Why did GKOS consistently beat earnings estimates?

Glaukos Corporation (GKOS) consistently beat earnings estimates due to several key factors: 1. **Strong Product Demand**: The success of Glaukos' flagship product, iStent, has been a significant driver of revenue. The company reported robust performance in 2024, with strong demand for its international glaucoma and Corneal Health products. The adoption of iStent Infinite for glaucoma patients, particularly those unresponsive to other treatments, has been increasing, fueled by enhanced clinical education and improved market access. 2. **New Product Launches**: The launch of iDose TR in the second quarter of 2024 has already enhanced revenue growth. Glaukos' introduction of iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant, has been well-received in the market. 3. **Strategic Initiatives**: Glaukos' focus on developing and implementing training programs for surgeons has supported the future growth of its products. The company's efforts to get iDose TR featured in peer-reviewed journals as an alternative treatment for glaucoma and ocular hypertension have also contributed to its growth. 4. **Market Position**: Glaukos' market position in the ophthalmic medical technology and pharmaceutical sector, coupled with its robust product pipeline, positions it well for growth. The company's strong brand and reputation in the industry have also helped it capture a significant market share. In conclusion, Glaukos' consistent beating of earnings estimates can be attributed to its successful product launches, strong demand for its existing products, strategic initiatives, and its dominant market position. These factors have collectively contributed to the company's financial success and growth.